News Bayer files HER2+ lung cancer drug in China Bayer files its oral HER2+ lung cancer drug in China, as it extends a race to market with rival Boehringer Ingelheim.
News Survival data back Tagrisso's role in first-line lung cancer Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?
News Dizal set to bring lung cancer drug Zegfrovy to US Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.
News Nuvalent chases after Nuvation in ROS1 lung cancer New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.
News AZ, Daiichi get Datroway nod in lung cancer on second try AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.
News FDA clears Nuvation's first product Ibtrozi, for lung cancer Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
